Polymorphisms (single-nucleotide polymorphism (SNP)) in the interleukin-7 receptor-a (IL-7Ra)/IL-7 pathway are associated with an increased risk to develop multiple sclerosis (MS). The rs6897932 SNP in the IL-7Ra leads to increased soluble IL-7Ra production. Given the functional interaction between sIL-7Ra, membrane-bound IL-7Ra and IL-7, we assessed IL-7, mIL-7Ra and sIL-7Ra levels in MS patients and healthy controls (HCs). One-hundred and twenty eight MS patients had significantly lower sIL-7Ra levels compared with 73 HCs. The levels of sIL-7Ra increased dose-dependent upon rs6897932 [C] risk allele carriership in both HCs and MS. Next, we hypothesized that lower sIL-7Ra could result in a higher mIL-7Ra to soluble IL-7Ra ratio. Indeed, 52 MS patients had significantly increased mIL-7Ra to sIL-7Ra ratio for both CD4 and CD8 T cells compared with 44 HCs. Given the supposed role of IL-7 in autoimmunity, we determined whether sIL-7Ra influences IL-7 levels. IL-7 levels were significantly decreased in 40 MS patients compared with 40 HCs. In conclusion, MS patients had lower free IL-7 and a higher membrane to soluble IL-7Ra ratio. The soluble IL-7Ra levels correlate with the rs6897932 [C] risk allele carriership. The skew at the IL-7 and IL-7Ra level may influence responsiveness of IL-7Ra þ cells.
INTRODUCTION
One of the first non-HLA genetic polymorphisms found to be associated with an increased risk to develop multiple sclerosis (MS) is the interleukin-7 receptor a (IL-7Ra; rs6897932). [1] [2] [3] Recently, also a detailed genetical analysis found associations with MS risk at different levels in the entire IL-7Ra pathway, for example, in the IL-7 gene itself and in the downstream signaling molecules TYK2 and SOCS1 involved in cytokine signaling and secretion. 4 The IL-7Ra/IL-7 axis is an interesting candidate in autoimmunity, because it is an important survival factor for CD4 and CD8 T cells, and is involved in early B-cell development. 5 Interestingly, IL-7Ra is genetically implicated in other autoimmune diseases, like rheumatoid arthritis (RA) 6 and type I diabetes mellitus. 7 Increased expression of the IL-7Ra on T-and B-lymphocytes and macrophages in RA and undifferentiated arthritis compared with osteoarthritis was found in the inflamed joint. 8 A transfection study showed that the MS risk single-nucleotide polymorphism (SNP) rs6897932 [C] caused more exon 6 mRNA splicing, which encodes the transmembrane domain of the receptor, 3 potentially leading to altered soluble levels of the receptor. A recent study correlated rs6897932 [C] with sIL-7Ra on protein level, but could not detect differences between MS patients and controls. 9 However, this study did not investigate whether sIL-7Ra levels correlate with altered membrane-bound IL-7Ra levels. A single study showed higher IL-7 mRNA levels in the mononuclear cells in CSF of MS patients compared with other neurological diseases without oligoclonal bands. 2 On the other hand only one study with MS patients in remission and during active disease exists for the protein level. 10 However, this study did not investigate IL-7 in the context of sIL-7Ra.
The aim of the current study was to assess in a larger and well specified cohort of MS patients whether differences between MS patients and healthy controls (HCs) occur and whether sIL-7Ra levels are genetically driven by the rs6897932 [C] polymorphism. Moreover, we assessed whether levels of soluble and membranebound IL-7Ra levels are correlated. As sIL-7Ra might alter unbound IL-7 levels, we determined IL-7 levels to investigate aberrancies in the IL-7/IL-7Ra axis in MS patients.
RESULTS AND DISCUSSION
We assessed the concentration of soluble IL-7Ra in plasma of MS patients (n ¼ 128) and HCs (n ¼ 73) ( , P ¼ 0.04), Figure 1a . This is an unexpected finding, because the frequency of the rs6897932 [C] SNP is increased in MS patients, which supposedly causes increased splicing of exon 6 of the IL-7Ra. To test whether this SNP correlates with sIL-7Ra level, we stratified these results according to rs6897932 [C] risk carriership. In both MS patients and HCs, the C-allele risk carriership indeed strongly correlates with higher levels of the sIL-7Ra. A dose-dependent increase of the sIL-7Ra was found in C-allele risk carriers (Figure 1b ). Homozygous C risk carriers had significantly (Po0.0001) more sIL-7Ra (median 75.6 ng ml À 1 , IQR 56.7-97.9 ng ml À 1 , n ¼ 59) compared with 41.2 ng ml À 1 (IQR 27.9-60.7 ng ml À 1 risk carriers and 16.0 ng ml À 1 (IQR 10.2-57.47 ng ml
, n ¼ 7) in the TT non-risk carriers. In HCs, the same association was observed (Po0.0001), confirming a previous study. 9 No significant differences were found between 17 primary-progressive, 23 secondaryprogressive, 82 relapsing-remitting MS patients and 6 clinically isolated syndrome patients (Figure 1c) . Additionally, no differences were observed between 40 MS patients treated with immunomodulating therapy and 88 untreated MS patients (Figure 1d) .
A possible consequence of the decreased level of sIL-7Ra is an increased level of circulating free IL-7. To address the question whether IL-7 levels are altered in MS patients, we determined the IL-7 concentration in serum of a subset of MS patients (n ¼ 40) and HCs (n ¼ 40). In the MS group serum IL-7 levels were slightly but significantly decreased (median MS 9.3 pg ml À 1 , IQR 7.8-12.8 pg ml À 1 vs HC 11.3 pg ml
, IQR 8.9-14.0 pg ml À 1 , P ¼ 0.03, Figure 2) . This finding appears in contrast with a recent study by Haas et al. 10 that described increased levels of systemic IL-7. This discrepancy may be explained by differences in the level of disease activity (our study included patients in remission only). 
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36 (8) 43 (11) 48 (9) 51 (11) 41 (13 Of note, three CIS patients developed RR-MS after sIL-7Ra quantification. The remaining three CIS patients were respectively followed for 3, 24 and 53 months.
Aberrant systemic IL-7/IL-7Ra axis in MS KL Kreft et al IL-7 is an important cytokine, expressed mainly in the thymus, bone marrow and lymphoid tissues, where it facilitates T-cell development and expansion, thereby contributing to the homeostasis of the peripheral T-cell pool. 11 No studies exist on the expression of IL-7 in the thymus of MS patients vs HCs. It can be hypothesized that these lower systemic IL-7 levels also reflect lower thymic IL-7 levels, which might contribute to the lower number of recent thymic emigrants observed in MS. 12 Moreover, IL-7Ra signaling is required for intrathymic regulatory T-cell development. 13 Recently, it was shown that the receptor affinity of the soluble form is comparable to that of the membrane-bound IL-7Ra 14 and that the soluble receptor can inhibit IL-7 signaling in CD8 T cells of HIV patients. 15 Therefore, we investigated whether our results are influenced by complexes between IL-7 and sIL-7Ra. First, we assessed whether the sIL-7Ra enzyme-linked immunosorbent assay (ELISA) is inhibited by IL-7 binding. Therefore, we preincubated the plasma of 36 MS and 52 HCs with 50 pg ml À 1 of IL-7 and compared the sIL-7Ra levels determined with the results obtained from untreated plasma. Preincubation with IL-7 did not influence the signal in both HCs and MS (paired t-test, respectively, P ¼ 0.41 and P ¼ 0.89), indicating that the results of the ELISA are not altered by binding of IL-7 to the sIL-7Ra (Figure 3a) . We did not observe a reduction in signals of sIL-7Ra up to 10.000 pM (equals 174.000 pg ml À 1 ) of IL-7 ( Figure 3b ). Next, we investigated whether the IL-7 ELISA signal is inhibited by binding of the sIL-7Ra to IL-7. Therefore, we preincubated serum with 250 ng ml À 1 of recombinant sIL-7Ra overnight. This did not result in an inhibition of the detection of IL-7 in both HCs and MS (paired t-test, respectively, P ¼ 0.52 and P ¼ 0.27, Figure 3c ). Concentrations of sIL-7Ra up to 10.000 ng ml À 1 did not have any inhibitory effect on IL-7 detection (Figure 3d ). Moreover, we assessed whether the IL-7 ELISA detects IL-7 bound to the sIL-7Ra. To measure such complexes, we set up an ELISA using anti-IL-7 as a primary antibody and anti-sIL-7Ra as a secondary antibody. No complexes were found using this approach in eight MS patients and eight age and gender HCs (data not shown). Using the reverse approach, now using anti-sIL7Ra as a capture antibody and anti-IL-7 as detection antibody, we found comparable results. Only in 1/29 MS patients and 1/34 HCs, sIL-7Ra/IL-7 complexes were detected (Figure 3e , positive control included recombinant IL-7 (35 nM) and sIL-7Ra (50 ng ml À 1 )). These observations indicate that it is not likely that complexes between IL-7 and sIL-7Ra have influenced the ELISA measurements. Comparable conclusions were drawn by Rose et al. 14 
Membrane expression of the IL-7Ra on most CD8 T-cell subsets is significantly increased in MS patients and the frequency of IL-7Ra
þ CD8 effector memory subset (CD8EM defined as CD27 À CD45RA À ) is significantly higher in MS patients. 16 Therefore, we investigated whether systemic concentrations of sIL-7Ra correlate with the level of IL-7Ra membrane expression on functional CD4 and CD8 lymphocyte subsets. We found that in 52 MS patients compared with 44 HCs the ratio between mean fluorescence intensity (an estimate for the number of receptors per cell) of IL-7Ra on both CD4 and CD8 T cells and the sIL-7Ra levels is significantly increased (Figures 4a and b , Po0.01. Equal differences were found in all functional CD4 and CD8 T-cell subsets, all Po0.01; data not shown). Previously, we showed that no correlation exist between levels of membrane IL-7Ra expression and the rs6897932 [C] MS risk genotype. 16 Hence, only the levels of the soluble IL-7Ra correlate with the risk genotype (Figure 1b) . It is conceivable that the lower serum concentrations of 'unbound' IL-7 and 'free' sIL-7Ra, in conjunction with the increased membrane-bound IL-7Ra found in MS patients, lead to an increased IL-7 responsiveness when IL-7 binds to the membrane-bound receptor. The increased ratio of membrane to soluble IL-7Ra in MS patients in conjunction with the increased frequency of CD8EM coexpressing the IL-7Ra is of potential interest, because these cells are specialized in tissue invasion and homing within inflamed organs. 17 Increased IL-7Ra signaling capacities were observed in CD8 T cells of MS patients, leading to increased mRNA expression of cytotoxic molecules. 16 Moreover, altered expression of both the membrane and soluble form potentially provides a survival advantage, as membranebound IL-7Ra signaling prevents activation induced cell death. 18 Reactive astrocytes in MS white matter brain lesions produce IL-7, 19 suggesting that the potential increased IL-7 responsiveness of CD8 T cells leads to enhanced cytotoxic responses in the brain, potentially inducing tissue damage. Moreover, this locally produced IL-7 in the brain may contribute to local expansion of these T cells.
Whether IL-7 levels along with membrane and soluble IL-7Ra expression are altered during different phases of disease activity in RR-MS patients (for example, during relapses vs in remissions) deserves to be further studied.
In conclusion, we showed that MS patients have lower systemic levels of IL-7 and sIL-7Ra and increased ratio of membrane-bound to soluble IL-7Ra. This might facilitate cellular responses by cells expressing high levels of IL-7Ra, which are potentially autoreactive lymphocytes ( Figure 5 ). The sIL-7Ra levels are genetically driven by the rs6897932 [C] MS risk SNP. Targeting the IL-7Ra pathway might be a promising therapeutic intervention in MS and other in autoimmune diseases, for example, RA. 20 
MATERIALS AND METHODS

Patients and controls
Consecutive MS patients diagnosed according to the McDonald criteria for MS 21 were included in this study. A relapse or the usage of methylprednisolone 3 months before sampling were exclusion criteria. HCs were relatives of the MS patients. HCs with prior neurological symptoms suggestive for MS, such as optic neuritis or myelitis or the diagnosis of MS or the usage of any immunomodulating therapy for other autoimmune diseases, were exclusion criteria. This study was approved by the Medical Ethical Committee of the Erasmus MC and written informed consent was obtained from all patients and controls. sIL-7Ra ELISA Plasma samples were collected using CPT Heparin Tubes (BD, Plymouth, UK) and processed according to the manufacturers protocol. The ELISA for sIL-7Ra was used as previously described.
14 Briefly, a capture antibody (monoclonal mouse anti-human IL-7Ra antibody, clone 40131, R&D Systems, Minneapolis, MN, USA) was coated overnight onto Nunc Maxisorb 96-well plates (Nunc, Roskilde, Denmark). Hundred microliter plasma was incubated at room temperature for 1 h under constant shaking and a detection antibody directly biotinylated was subsequently added for 1 h (biotinylated goat anti-human IL-7Ra antibody, R&D Systems), followed by TMB substrate reaction detected at 450 nm wavelength and corrected for a 605 nm wavelength. Recombinant human IL-7Ra (R&D systems) was used to make a standard curve and the detection limits of this ELISA were 21 and 300 ng ml
To assess whether the results of the sIL-7Ra ELISA are influenced by IL-7 binding to the sIL-7Ra, plasma samples were preincubated with 50 pg ml À 1 of IL-7 (Peprotech, Rocky Hill, NJ, USA) overnight at room temperature. Moreover, a linear dilution of IL-7 was used to assess whether high concentrations of IL-7 are able to block the sIL-7Ra detection in the ELISA. After the incubation of recombinant proteins, sIL-7Ra was assessed as described and compared with the same plasma sample without addition of IL-7.
IL-7 ELISA Serum samples of 40 MS patients and 40 HCs were drawn using coagulation tubes (BD) and samples were processed according to the manufacturers' protocol and stored at À 80 1C until analysis. Two-hundred and fifty microliter of serum was analyzed for IL-7 according to the manufacturers' protocol (Quantikine HS IL-7 ELISA, R&D Systems). The detection range was between 0.22-14.79 pg ml þ cells was determined and the ratio between membrane-bound IL-7Ra and sIL-7Ra levels in plasma obtained from the same sample was determined in 44 HC and 52 MS patients.
whether the detection of IL-7 in this ELISA is influenced by binding of IL-7. Therefore, serum was preincubated with 250 ng ml À 1 recombinant sIL-7Ra overnight and IL-7 levels were determined as described in 'untreated' and preincubated serum. Moreover, a linear dilution of the sIL-7Ra in serum samples was used to determine whether high concentrations of sIL-7Ra would inhibit the detection of IL-7.
Qualitative ELISA to detect complexes of sIL-7Ra and IL-7
Plasma and serum samples were assessed for the presence or absence of complexes between the sIL-7Ra and IL-7. The capture antibody against the IL-7Ra (monoclonal mouse anti-human IL-7Ra antibody, clone 40131, R&D Systems) was coated overnight onto Nunc Maxisorb 96-well plates. Plasma and serum was incubated, with constant shaking, at room temperature for 1 h. Subsequently, a directly biotinylated antibody against IL-7 (biotinylated goat anti-human IL-7 antibody, R&D Systems) was used as detection antibody, followed by a TMB substrate reaction detected at 450 nm wavelength and corrected for the 605 nm wavelength. recombinant human sIL-7Ra (50 ng ml À 1 ) and IL-7 (5 nM) was incubated at room temperature overnight to form complexes.
Flowcytometry
Peripheral blood mononuclear cells were isolated from CPT tubes (BD), liquid nitrogen frozen until flowcytometric analysis. 1*10E6 peripheral blood mononuclear cells of 44 HCs and 52 MS patients were stained with mouse monoclonal anti-human antibodies against CD3 FITC (clone SK7), CD4 PE-Cy7 (clone SK3), CD8 APC-Cy7 (clone SK1), CD27 APC (clone L128), CD45RA PerCp-Cy5.5 (clone HI100) and CD127 PE (IL-7Ra, clone eBioRDR5). All antibodies were obtained from BD Biosciences (Erembodegem-Aalst, Belgium), except CD45RA PerCP-Cy5.5 and CD127 PE (eBioscience, San Diego, CA, USA). Samples were measured on a bead-calibrated LSR II (BD Biosciences) and data was analyzed with Facs Diva 6.1 software (BD Biosciences, Franklin Lakes, NJ, USA).
Genotyping
Genotype data were obtained using either Illumina Affymetrix 650k (Affymetrix, Franklin Lakes, NJ, USA) or Taqman genotype assay (assay id C_2025977_10; Applied Biosystems, Carlsbad, CA, USA). All assays were performed according to the manufacturers' protocol. In all assays, the standard call rate was 495%. All water controls were successful, the CEPH-A and CEPH-B were concordant and all duplicates were concordant. Both cases and controls were in Hardy-Weinberg equilibrium (respectively, P ¼ 0.98 and 0.89).
Statistical analysis
Differences were tested using a Mann-Whitney U-test (comparing two groups) or non-parametric one-way analysis of variance (comparing multiple groups) using SPSS version 17 (SPSS Inc, Chicago, IL, USA). For the inhibition ELISA for IL-7 and sIL-7Ra, a paired t-test was used. P-values o0.05 were considered significant and are denoted in the figures as *Po0.05, **Po0.01 and ***Po0.001. Figure 5 . Model of the altered IL-7/sIL-7Ra/mIL-7Ra axis in MS. MS patients have lower levels of IL-7 and sIL-7Ra, but the ratio between these two parameters is increased. Moreover, the ratio between mIL-7Ra and sIL-7Ra in MS is significantly increased, thereby facilitating aberrant activation of potentially auto-reactive T cells.
